Mani (TSE:7730) Stock Earnings Growth And 18.8% Margin Reinforce Bullish Narratives

Mani (TSE:7730) has reported Q3 2026 results with revenue of ¥8.3b and basic EPS of ¥17.70, set against trailing 12 month totals of ¥32.1b in revenue and ¥61.23 in basic EPS that reflect 14.7% earnings growth over the past year. The company has seen quarterly revenue move from ¥7.2b in Q2 2025 to ¥8.3b in Q3 2026, while quarterly basic EPS has tracked from ¥13.62 to ¥17.70 over the same period, with earnings growth of 5.3% per year over the last five years and forecasts pointing to about 12.1% annual earnings growth and 8.4% annual revenue growth. With trailing net profit margin at 18.8% versus 17.9% a year earlier, this set of numbers points to a story that is increasingly about the quality and resilience of Mani's margins.

See our full analysis for Mani.

With the headline figures in place, the next step is to see how Mani's recent earnings and margin profile line up against the key market narratives investors follow around growth, risk, and sustainability.

See what the community is saying about Mani

Margins and net income point to earnings quality

• Q3 2026 net income excluding extra items came in at ¥1,744 million on revenue of ¥8,290 million, while trailing 12 month net income reached ¥6,031 million on ¥32,084 million of revenue, aligning with the 18.8% net profit margin cited for Mani.
• Consensus narrative highlights expectations for margins to move from 17.9% to 22.7% over the next few years. The current 18.8% trailing margin and Q3 net income level show Mani is still some distance from that target, which invites investors to consider how quickly cost efficiencies and new products will translate into the higher profitability analysts are incorporating into their assumptions.
  • Forecasts referenced in the consensus narrative point to earnings growth of about 12.1% per year, so the current ¥6,031 million of trailing net income becomes a reference point for whether that path is being followed.
  • With revenue expected to grow about 8.4% per year from a ¥32,084 million base, any gap between actual and expected margin expansion will matter for how comfortably Mani can reach the future earnings levels analysts are using in their models.

Quarterly EPS trend versus bullish growth story

• Across the last three quarters of 2026, Mani reported basic EPS of ¥19.25 in Q1, ¥20.32 in Q2 and ¥17.70 in Q3, against trailing 12 month EPS of ¥61.23 that sits above the prior year and ties in with 14.7% earnings growth over the past year.
• Bullish analysts focus on earnings climbing from about ¥5,601 million of trailing net income a year ago to ¥6,031 million now and forecast earnings growth of around 12.1% per year. The recent quarter to quarter EPS pattern reminds investors that even within an upward long term trend, individual quarters can move around and should be read in the context of the longer trailing 12 month line rather than as a straight line from one quarter to the next.
  • The bullish narrative also points to expected earnings of ¥9.2 billion by around 2029, so the current ¥6,031 million trailing net income shows Mani partway along that path, with the 14.7% year on year earnings growth providing some numerical backing to that view.
  • At the same time, the Q3 EPS of ¥17.70 compared with Q2’s ¥20.32 gives a reminder that short term fluctuations can appear even when the trailing 12 month EPS trend is aligned with a growth story.

For investors who want to see how these quarterly shifts fit into a fuller optimistic storyline for Mani, it is worth reading the dedicated bull case analysis in the 🐂 Mani Bull Case.

Premium P/E and DCF fair value tension for Mani

• Mani trades on a trailing P/E of 25.8x at a share price of ¥1,577, compared with an industry average of 16.6x and peer average of 19.7x, while the DCF fair value in the data is ¥2,186.69, which sits above both the current price and the single allowed analyst price target of ¥1,940.00.
• Bearish commentary points to the relatively high P/E compared with the Japan medical equipment industry. The same dataset includes a DCF fair value and analyst expectations that revenue will grow about 8.4% per year and earnings about 12.1% per year, so anyone leaning on the cautious view has to weigh the premium multiple against signals that the current ¥1,577 price is below both fundamental and target based reference points.
  • The DCF fair value of ¥2,186.69 is higher than the analyst target of ¥1,940.00, and both exceed the current price, which contrasts with a purely valuation based bearish stance that focuses only on the premium P/E.
  • With no major risks highlighted in the provided dataset apart from an unstable dividend history, the bearish focus on valuation and dividend stability sits against a backdrop of 14.7% trailing earnings growth and 18.8% net margins that are above last year’s 17.9% level.

If you want to see how more cautious investors frame those valuation and margin trade offs for Mani, take a look at the focused bear case write up in the 🐻 Mani Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Mani on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both optimism and caution around Mani in this article, it makes sense to check the underlying data yourself and decide where you stand. To balance the concerns and potential upside that other investors are focused on, take a closer look at the 4 key rewards and 1 important warning sign.

See What Else Is Out There Beyond Mani

While Mani shows solid earnings and margins, the premium 25.8x P/E against lower industry and peer averages raises questions about how much potential is already reflected in the price.

If you are uneasy about paying up for Mani at this kind of valuation, it is worth spending a few minutes checking stocks screened as 18 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com